2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: ...

Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series ...

Welcome to the Fierce Biotech Graveyard, a yearly ritual where we remember all the biotechs we lost in 2025. While we're ...

Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in ...

iShares Biotechnology ETF (IBB) offers targeted exposure to the U.S. biotechnology sector, providing investors with access to ...

A well-crafted narrative helps investors see not just the molecule in front of them, but the broader therapeutic and ...

Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo!

Dimitri Semenikhin, the retail trader behind the Beyond Meat stock rally is piling into a small biotech that recently pivoted ...

Editor’s Note: This deep dive was originally published Sept. 24, 2025, as a special edition of Biopharm Executive. Subscribe ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

The U.S. inked Technology Prosperity Deals (TPD) with Japan and South Korea with an eye toward spurring collaboration on AI, ...

Genmab A/S (NASDAQ: GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju ...